Precision Transcriptional Interference for Reversible Metabolic Tuning and High-Throughput Screening. In the complex landscape of yeast metabolic engineering, permanent gene knockouts are not always the optimal solution—especially when dealing with essential genes or the need for delicate flux balancing. CD Biosynsis provides professional Yeast CRISPRi (CRISPR Interference) Services, offering a powerful, non-cytotoxic, and reversible platform for gene silencing. By utilizing catalytically inactive Cas proteins (dCas9/dCas12a) fused to transcriptional repressors, we enable the precise "dialing down" of gene expression to optimize industrial yeast strains for biofuels, specialty chemicals, and high-value metabolites.
Get a Technical QuoteOur CRISPRi platform provides a versatile toolkit for exploring the yeast phenome and redirecting metabolic pathways without the permanence of genomic deletions. We offer specialized solutions for both model and non-conventional industrial yeast hosts.
| Service Tier | Technical Strategy | Best For | Standard Deliverables |
|---|---|---|---|
| Custom Metabolic Tuning | Targeted dCas9-Repressor Fusion | Balancing competing pathways / Essential gene study | Validated knockdown strains + qPCR data |
| High-Throughput Screening | Large-scale sgRNA Libraries | Identifying stress-tolerance & growth genes | Screening report + Validated gene targets |
| Editing Enhancement | NHEJ Pathway Repression | Improving HR rates in non-conventional yeast | High-efficiency editing strains (e.g., Y. lipolytica) |
| Flux Balancing | Multiplex Transcriptional Silencing | Redirecting carbon flow to target products | Engineered production strains + Yield analysis |
1. Target Selection & Design
2. System Construction
3. Transformation & Tuning
4. Validation & Scale-up
Identifying metabolic bottlenecks and designing high-specificity sgRNAs targeting the promoter or TSS regions.
Formal project proposal and Mutual NDA signing.
Building customized CRISPRi vectors with optimized repressors tailored for specific yeast species.
Design of large-scale sgRNA libraries for high-throughput phenotypic screening.
Introducing CRISPRi machinery into industrial strains and high-throughput evaluation under stress conditions.
Titration of gene expression levels to optimize product titer and host fitness.
Quantifying knockdown efficiency via RT-qPCR and assessing engineered strains in pilot fermentation trials.
Final delivery of optimized strains and comprehensive metabolic characterization reports.
To deliver world-class results, our technical team continuously monitors and benchmarks our protocols against landmark research in the field. These studies demonstrate the diverse potential of CRISPRi in industrial biotechnology.
Identifying genes that confer resistance to toxic compounds in lignocellulose hydrolysates is crucial for biofuel production. Utilizing a single-plasmid CRISPRi system to target transcription factors and protein kinases, research has successfully identified key regulators of yeast growth in these inhibitory environments. This approach facilitates the development of robust yeast strains capable of high-efficiency bio-ethanol fermentation from sustainable feedstocks.
(Reference: Gutmann et al., EMBO Journal, 2021)
For non-conventional industrial yeast like Y. lipolytica, low homologous recombination (HR) rates often hinder metabolic engineering. By using CRISPRi to provide a "soft knockdown" of the NHEJ pathway genes Ku70 and Ku80, technical benchmarks have shown HR rates reaching up to 90%. This reversible inhibition avoids the permanent growth disadvantages of traditional knockouts, simplifying the construction of high-yield strains for fatty acids.
(Reference: Schwartz et al., Biotechnology & Bioengineering, 2022)
Systematic study of the yeast phenome requires tools that can modulate gene expression across the entire genome. Large-scale CRISPRi libraries covering nearly all S. cerevisiae genes have been utilized to screen for critical industrial phenotypes, such as tolerance to high alcohol and acidic conditions. This platform provides a powerful framework to rapidly identify gene combinations that optimize growth under specific fermentation stresses.
(Reference: McGlincy et al., Cell, 2020)
Metabolic flux balancing is essential for maximizing high-value aroma compounds. By using CRISPRi to repress mitochondrial respiratory functions, research has successfully redirected carbon flow toward the ethyl acetate synthesis pathway. Targeted silencing of key respiratory genes led to increased levels of Acetyl-CoA, significantly boosting the production of ethyl acetate for flavors and fragrances.
(Reference: Lobs et al., ACS Synthetic Biology, 2020)
1. How does CRISPRi compare to traditional RNAi for gene repression in yeast?
CRISPRi acts at the DNA level by blocking transcription directly, whereas RNAi targets mRNA in the cytoplasm. CRISPRi generally provides more stable, consistent, and potent repression with fewer off-target effects in most yeast species.
2. Is it possible to multiplex CRISPRi to target multiple metabolic pathways simultaneously?
Yes. Our platform is optimized for multiplexing, allowing for the simultaneous repression of multiple genes. This is ideal for complex metabolic rewiring where several competing pathways must be suppressed to maximize a single target product.
3. Can CRISPRi be used in diploid or polyploid industrial yeast strains?
Absolutely. Our CRISPRi systems utilize high-efficiency promoters and optimized dCas9 expression to ensure effective repression across multiple gene copies, a critical requirement for industrial Saccharomyces strains.
4. What is the typical turnaround time for a custom CRISPRi project?
Custom strain construction and validation via qPCR typically take approximately 4 to 8 weeks, depending on the complexity of the gene targets and the specific yeast host requirements.
5. How do you ensure the stability of the CRISPRi system during long-term fermentation?
For long-term industrial applications, we recommend genomic integration of the dCas9 and sgRNA cassettes. This ensures maximum stability without the need for continuous antibiotic selection during large-scale fermentation.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.